Literature DB >> 12122729

Medical therapy for ulcerative colitis.

Niraj Jani1, Miguel D Regueiro.   

Abstract

Although newer therapeutic agents are being developed for the treatment of inflammatory bowel disease, aminosalicylates and corticosteroids remain the mainstay of treatment for UC (Tables 2-5). Patients who do not respond to these agents or become steroid dependent require immunomodulatory therapy or curative surgery. Cyclosporine represents the greatest treatment advance for UC in 10 years. The role of nicotine, heparin, antibiotics, probiotics, and SCFA in the treatment of UC is less clear, but these agents may offer an alternative therapeutic approach for patients intolerant or nonresponsive to standard therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12122729     DOI: 10.1016/s0889-8553(01)00010-3

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  8 in total

Review 1.  PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Man Cai Wang; Ling Yi Zhang; Wei Han; Yuan Shao; Mo Chen; Rui Ni; Gen Nian Wang; Feng Xian Wei; Ya Wu Zhang; Xiao Dong Xu; You Cheng Zhang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

2.  Chymase inhibitor TY-51469 in therapy of inflammatory bowel disease.

Authors:  Wei-Xin Liu; Ying Wang; Li-Xuan Sang; Shen Zhang; Ting Wang; Feng Zhou; Shou-Zhi Gu
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

3.  Inhibitory effect of heparin-derived oligosaccharides on secretion of interleukin-4 and interleukin-5 from human peripheral blood T lymphocytes.

Authors:  Sheng-Li Ji; Hui-Fei Cui; Feng Shi; Yan-Qing Chi; Ji-Chao Cao; Mei-Yu Geng; Hua-Shi Guan
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

Review 4.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 5.  Nicotine and inflammatory neurological disorders.

Authors:  Wen-Hua Piao; Denise Campagnolo; Carlos Dayao; Ronald J Lukas; Jie Wu; Fu-Dong Shi
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

6.  Effects of Rheum tanguticum polysaccharide on TNBS -induced colitis and CD4+T cells in rats.

Authors:  Li Liu; Zhi-Peng Wang; Chang-Tai Xu; Bo-Rong Pan; Qi-Bing Mei; Yin Long; Jia-Yun Liu; Si-Yuan Zhou
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

Review 7.  Key role of mast cells and their major secretory products in inflammatory bowel disease.

Authors:  Shao-Heng He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

8.  Decreasing Colectomy Rates in Ulcerative Colitis in the Past Decade: Improved Disease Control?

Authors:  Hassan Ghoz; Alex Kesler; Sanne A Hoogenboom; Filippo Gavi; Bhaumik Brahmbhatt; John Cangemi; Paul T Kröner
Journal:  J Gastrointest Surg       Date:  2019-12-03       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.